Price History

Hover for the daily close. The dotted line marks the period open.

Compare PROK with… →

PROK Key Statistics

As of Sep 4, 2026

Trading

Open: $1.90
Previous Close: $1.92
Day's Range: 1.89–2.09
52-Week Range: 1.30–3.48
Volume: 1.22M
Beta: 1.75

Valuation

Market Cap: $802.36M
P/E Ratio: unprofitable
P/S ratio: 980.88
EPS (ttm): −0.57

Financials (FY)

Revenue (FY): $893.00K+1075.00%
Net Income (FY): −$68.99M
Profit margin: 0.00%
Shares Outstanding: 208.93M
1-Year Return: −12.61%

Dividend and dates

Earnings Date: November 9, 2026estimated
Avg Volume: 1.20M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PROK Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−2.08%−30.71%−74.05%−5.06%+32.54%−10.27%

2021*20222023202420252026*

Year	Return
2026 (partial year)	−10.27%
2025	+32.54%
2024	−5.06%
2023	−74.05%
2022	−30.71%
2021 (partial year)	−2.08%

As of September 4, 2026.

PROK Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$893.00K	−$68.99M	−7725.2%
2024	$76.00K	−$61.19M	−80507.9%
2023	$0.00	−$35.47M	—
2022	$0.00	−$108.03M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$893.00K	—	−$165.01M	−$68.99M	−7725.2%
2024	$76.00K	—	−$183.68M	−$61.19M	−80507.9%
2023	$0.00	—	−$151.52M	−$35.47M	—
2022	$0.00	—	−$153.01M	−$108.03M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PROK Valuation vs Biotechnology Median

Median of 656 stocks

Metric	PROK	Biotechnology median	vs median
P/S ratio	980.88	15.26	64.3x the median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

ProKidney Corp. (PROK) carries a market capitalisation of $802.36M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 231 employees.

PROK last closed at $2.01 on September 4, 2026. That is +$0.09 (+4.69%) against the previous close. The 52-week range on file runs from $1.30 to $3.48. The latest close sits 54.62% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $893.00K. Against the prior fiscal year total of $76.00K, that is a change of +1,075.00%. The same year closed with a net loss of $68.99M. The reported profit margin is 0%. Trailing earnings per share are −0.57.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $893.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 980.88 times revenue. On price-to-sales that is 64.3 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 1.75. Annualized volatility over the trailing 5 years is 251.87%. Over the trailing twelve months the price has returned −12.61%. Across 5 years the annualized return works out at −27.08%.

Growth & Income

The record shows no dividend for PROK.

Across the complete calendar years on file, 2025 returned +32.54% and 2023 returned −74.05%. Of the 4 complete calendar years on file, 1 finished higher. 2026 is still running; the price is −10.27% year to date.

Peer Comparison

ProKidney Corp. (PROK) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
ProKidney Corp.	PROK	$802.36M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. ProKidney Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About ProKidney Corp.

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Visit website →

ProKidney Corp. (PROK) Stock Analysis